{"entity":{"id":"nct07156565","kind":"trial","name":"Actinium Therapy for Late-stage Aggressive Sarcomas","aka":[],"tldr":"A phase 1 trial of [Ac-225]RTX-2358 run by Ratio Therapeutics, Inc., now recruiting.","summary":"Actinium Therapy for Late-stage Aggressive Sarcomas is a phase 1 interventional study registered as NCT07156565 by Ratio Therapeutics, Inc., with 48 participants planned, started 2025-11-12. Conditions recorded: Advanced Soft Tissue Sarcoma. Interventions recorded: [Ac 225]RTX-2358 and [Cu64]LNTH-1363S.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07156565","url":"https://clinicaltrials.gov/study/NCT07156565"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["extremity-soft-tissue-sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":["rtx-2358"],"companies":["ratio-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07156565","phase":"1","setting":"A Seamless Phase 1/2 Open-label Study to Evaluate the Safety, Determine the Maximum Tolerated Dose of Administered Activity, and Evaluate the Efficacy of the Therapeutic Radiopharmaceutical [Ac 225]-RTX-2358 in the Treatment of Relapsed or Refractory Sarcoma","sponsor":"Ratio Therapeutics, Inc.","enrolled":48,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07156565/","neighbours":{"cancer":[{"id":"extremity-soft-tissue-sarcoma","kind":"cancer","name":"Soft tissue sarcoma of the extremity (localised and advanced)","route":"/cancers/extremity-soft-tissue-sarcoma/"}],"drug":[{"id":"rtx-2358","kind":"drug","name":"[Ac-225]RTX-2358","route":"/drugs/rtx-2358/"}],"company":[{"id":"ratio-therapeutics","kind":"company","name":"Ratio Therapeutics","route":"/companies/ratio-therapeutics/"}]}}